Inhibition of TRIM32 Induced by miR-519d Increases the Sensitivity of Colorectal Cancer Cells to Cisplatin

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.2125425559415
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–259. doi:10.1097/01.sla.0000217629.94941.cf16858188
   PubMed Web of Science ®Google Scholar
• Yao Y, Rao C, Zheng G, Wang S. Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR-384/pleiotrophin axis. Oncol Rep. 2019;42:131–141. doi:10.3892/or.2019.713631059061
   PubMed Web of Science ®Google Scholar
• LCiombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66:83–95. doi:10.1146/annurev-med-051513-10253925341011
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.6527189416
   PubMed Web of Science ®Google Scholar
• Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015;21:5158–5166. doi:10.3748/wjg.v21.i17.515825954089
   PubMed Web of Science ®Google Scholar
• Wang S, Li J, Yang X. Long non-coding RNA LINC00525 promotes the stemness and chemoresistance of colorectal cancer by targeting miR-507/ELK3 axis. Int J Stem Cells. 2019;12:347–359. doi:10.15283/ijsc1904131242722
   PubMed Web of Science ®Google Scholar
• Li Y, Li C, Li D, Yang L, Jin J, Zhang B. lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. Onco Targets Ther. 2019;12:2649–2660. doi:10.2147/OTT.S18805431040703
   PubMed Web of Science ®Google Scholar
• Chi YD, Zhou DM. MicroRNAs in colorectal carcinoma–from pathogenesis to therapy. J Exp Clin Cancer Res. 2016;35:43. doi:10.1186/s13046-016-0320-426964533
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2007;131:11–29. doi:10.1016/s0092-8674(04)00045-5
   Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33:1126–1133. doi:10.1093/carcin/bgs14022491715
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314. doi:10.1146/annurev-pathol-012513-10471524079833
   PubMed Web of Science ®Google Scholar
• Wang H, Deng Z, Chen X, et al. Downregulation of miR-222-3p reverses doxorubicin-resistance in lovo cells through upregulating forkhead box protein P2 (FOXP2) protein. Med Sci Monit. 2019;25:2169–2178. doi:10.12659/MSM.91332530904920
   PubMed Web of Science ®Google Scholar
• Liang H, Xu Y, Zhang Q, et al. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells. Artif Cells Nanomed Biotechnol. 2019;47:725–736. doi:10.1080/21691401.2019.156953030861353
   PubMed Web of Science ®Google Scholar
• Lei W, Yan C, Ya J, Yong D, Yujun B, Kai L. MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC Cancer. 2018;18:631. doi:10.1186/s12885-018-4460-029866054
   PubMed Web of Science ®Google Scholar
• Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F, Pelicci PG. TRIM proteins in cancer. Adv Exp Med Biol. 2012;770:77–91. doi:10.1007/978-1-4614-5398-7_623631001
   PubMed Web of Science ®Google Scholar
• Ozato K, Shin DM, Chang TH, Morse HC. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8:849. doi:10.1038/nri241318836477
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Fu H, et al. TRIM32 promotes cell proliferation and invasion by activating β-catenin signalling in gastric cancer. J Cell Mol Med. 2018;22:5020–5028. doi:10.1111/jcmm.1378430079558
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Wang XL, et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 2014;21:1792–1804. doi:10.1038/cdd.2014.12125146927
   PubMed Web of Science ®Google Scholar
• Yao H, Sun Q, Zhu J. miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin. Exp Ther Med. 2019;17:4363–4370. doi:10.3892/etm.2019.750131086572
   PubMed Web of Science ®Google Scholar
• Yin A, Jiang Y, Zhang X, Zhao J, Luo H. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo. Eur J Pharmacol. 2010;649:120–126. doi:10.1016/j.ejphar.2010.09.04020869960
   PubMed Web of Science ®Google Scholar
• Li S, Ren B, Shi Y, et al. Notch1 inhibition enhances DNA damage induced by cisplatin in cervical cancer. Exp Cell Res. 2019;376:27–38. doi:10.1016/j.yexcr.2019.01.01430690027
   PubMed Web of Science ®Google Scholar
• Jin X, Tian S, Li P, et al. Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol. 2019;234:9605–9615. doi:10.1002/jcp.2764730352127
   PubMed Web of Science ®Google Scholar
• Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. 2019;25:1147–1155. doi:10.1158/1078-0432.CCR-18-224430305294
   PubMed Web of Science ®Google Scholar
• Surnar B, Kolishetti N, Basu U, et al. Reduction of cisplatin-induced ototoxicity without compromising its antitumor activity. Biochemistry. 2018;57:6500–6513. doi:10.1021/acs.biochem.8b0071230281285
   PubMed Web of Science ®Google Scholar
• Bian WG, Zhou XN, Song S, Chen HT, Shen Y, Chen P. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A. Eur Rev Med Pharmacol Sci. 2019;23:649–659. doi:10.26355/eurrev_201901_1687930720173
   PubMed Web of Science ®Google Scholar
• Turato C, Fornari F, Pollutri D, et al. MiR-122 targets SerpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma. J Clin Med. 2019;8:E171. doi:10.3390/jcm802017130717317
   PubMed Web of Science ®Google Scholar
• Deng X, Zhao Y, Wang B. miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression. Oncol Rep. 2015;34:2188–2194. doi:10.3892/or.2015.416026238950
   PubMed Web of Science ®Google Scholar
• Hou YY, Cao WW, Li L, et al. MicroRNA-519d targets MKi67 and suppresses cell growth in the hepatocellular carcinoma cell line QGY-7703. Cancer Lett. 2011;307:182–190. doi:10.1016/j.canlet.2011.04.00221524841
   PubMed Web of Science ®Google Scholar
• Xie Q, Wang S, Zhao Y, Zhang Z, Qin C, Yang X. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget. 2017;8:22003–22013. doi:10.18632/oncotarget.1578128423543
   PubMedGoogle Scholar
• Pang Y, Mao H, Shen L, Zhao Z, Liu R, Liu P. MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP. Onco Targets Ther. 2014;7:587–597. doi:10.2147/OTT.S6028924790458
   PubMed Web of Science ®Google Scholar
• Zhao JX, Liu H, Lv J, Yang XJ. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro. Eur Rev Med Pharmacol Sci. 2014;18:2428–2434.25268086
   PubMed Web of Science ®Google Scholar
• Liu J, Tang Q, Li S, Yang X. Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget. 2016;7:86446. doi:10.18632/oncotarget.1342427880721
   PubMedGoogle Scholar
• Huang G, Pan J, Ye Z, Fang B, Cheng W, Cao Z. Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget. 2017;8:104206–104215. doi:10.18632/oncotarget.2217129262633
   PubMedGoogle Scholar
• Park SB, Lee JH, Jeong WW, et al. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2. J Chemother. 2015;27:174–180. doi:10.1179/1973947814Y.000000023425604244
   PubMed Web of Science ®Google Scholar
• Zhang L, He L, Zhang H, Chen Y. Knockdown of MiR-20a enhances sensitivity of colorectal cancer cells to cisplatin by increasing ASK1 expression. Cell Physiol Biochem. 2018;47:1432–1441. doi:10.1159/00049083429940575
   PubMedGoogle Scholar